Saruparib

本周药品注册受理数据，分门别类呈现，一目了然。(6.29-7.5） 新药上市申请 药品名称 企业 注册分类 受理号 盐酸罗哌卡因缓释溶液 北京泰德制药股份有限公司 2.2 CXHS2600097 盐酸罗哌卡因缓释溶液 北京泰德制药股份有限公司 2.2 CXHS2600096 盐酸罗哌卡因缓释溶液 北京泰德制药股份有限公司 2.2 CXHS2600095 盐酸罗哌卡因缓释溶液 北京泰德制药股份有限公司 2.2 CXHS2600094 醋酸阿比特龙软胶囊 江苏和晨药业有限公司 2.2 CXHS2600093 安奈拉唑钠肠溶片 轩竹(北京)医药科技有限公司 2.4 CXHS2600092 注射用瑞康曲妥珠单抗 苏州盛迪亚生物医药有限公司 2.2 CXSS2600103 新药临床申请 药品名称 企业 注册分类 受理号 SYH2083滴眼液 上海翊石医药科技有限公司 1 CXHL2600796 SYH2083滴眼液 上海翊石医药科技有限公司 1 CXHL2600795 SYH2083滴眼液 上海翊石医药科技有限公司 1 CXHL2600794 SYH2083滴眼液 上海翊石医药科技有限公司 1 CXHL2600793 QLS1510片 上海齐鲁制药研究中心有限公司 1 CXHL2600790 QLS1510片 上海齐鲁制药研究中心有限公司 1 CXHL2600789 MDR-001片 杭州德睿智药科技有限公司 1 CXHL2600788 MDR-001片 杭州德睿智药科技有限公司 1 CXHL2600787 注射用JY1001 浙江杭煜制药有限公司 1 CXHL2600792 HS-10582片 上海翰森生物医药科技有限公司 1 CXHL2600782 HS-10582片 上海翰森生物医药科技有限公司 1 CXHL2600781 YF550片 益祺生物科技(北京)有限公司 1 CXHL2600778 YF550片 益祺生物科技(北京)有限公司 1 CXHL2600777 注射用PTT-121 北京炎明生物科技有限公司 1 CXHL2600780 AHB-137注射液 杭州浩博医药有限公司 1 CXHL2600779 HCXT-2001片 上海瀚辰星泰医药科技有限公司 1 CXHL2600770 HCXT-2001片 上海瀚辰星泰医药科技有限公司 1 CXHL2600769 SZJ0107片 安徽三之健医药科技有限公司 1 CXHL2600774 BB3008片 北京伯汇生物技术有限公司 1 CXHL2600773 BB3008片 北京伯汇生物技术有限公司 1 CXHL2600772 OV329胶囊 缔脉生物医药科技(上海)有限公司 1 CXHL2600776 OV329胶囊 缔脉生物医药科技(上海)有限公司 1 CXHL2600775 注射用HHK101 珠海市华海康医药科技有限责任公司 2.2 CXHL2600783 SQ-23082滴眼液 沈阳兴齐眼药股份有限公司 2.2;2.4 CXHL2600786 SQ-23082滴眼液 沈阳兴齐眼药股份有限公司 2.2;2.4 CXHL2600785 SQ-23082滴眼液 沈阳兴齐眼药股份有限公司 2.2;2.4 CXHL2600784 F2008吸入粉雾剂 苏州易合医药有限公司 2.2;2.4 CXHL2600791 CZ028 浙江萃泽生物医药有限公司 2.2;2.4 CXHL2600771 CM336注射液 康诺亚生物医药科技有限公司 1 CXSL2600692 CM313(SC)注射液 康诺亚生物医药科技有限公司 1 CXSL2600695 CM313(SC)注射液 康诺亚生物医药科技有限公司 1 CXSL2600694 CM336注射液 康诺亚生物医药科技有限公司 1 CXSL2600693 HXN6005注射液 华深智药生物科技(苏州)有限公司 1 CXSL2600691 EA5注射液皮下制剂 上海览屹医药科技有限公司 1 CXSL2600688 乐德奇拜单抗注射液 先声药业有限公司 1 CXSL2600690 乐德奇拜单抗注射液 先声药业有限公司 1 CXSL2600689 注射用VDJ010 北京伟德杰生物科技有限公司 1 CXSL2600687 NW-301V注射液 新景智源生物科技(苏州)有限公司 1 CXSL2600686 人自体多克隆调节性T细胞注射液 上海赛尔欣生物医疗科技有限公司 1 CXSL2600685 注射用VBC106 上海橙帆医药有限公司 1 CXSL2600684 注射用HC029 上海宏成药业有限公司 1 CXSL2600681 OX-1胶囊 武汉康复得生物科技股份有限公司 1 CXSL2600680 SHR-4610注射液 上海盛迪医药有限公司 1 CXSL2600683 注射用HS-20093 上海翰森生物医药科技有限公司 1 CXSL2600682 GLR1075注射液 甘李药业股份有限公司 2.4 CXSL2600696 仿制药申请 药品名称 企业 注册分类 受理号 乙酰半胱氨酸片 广东赛康制药厂有限公司 3 CYHS2601581 注射用甲磺酸萘莫司他 康普药业股份有限公司 3 CYHS2601580 注射用甲磺酸萘莫司他 康普药业股份有限公司 3 CYHS2601579 铝碳酸镁混悬液 江苏晨牌邦德药业有限公司 3 CYHS2601578 依替巴肽注射液 天津天士力之骄药业有限公司 3 CYHS2601576 盐酸伐地那非口崩片 江西汇仁药业股份有限公司 3 CYHS2601584 吡格列酮二甲双胍片 北京太洋药业股份有限公司 3 CYHS2601583 枸橼酸西地那非口溶膜 广州白云山医药集团股份有限公司白云山制药总厂 3 CYHS2601564 司美格鲁肽注射液 浙江三生蔓迪药业有限公司 3 CYHS2601570 司美格鲁肽注射液 浙江三生蔓迪药业有限公司 3 CYHS2601574 司美格鲁肽注射液 浙江三生蔓迪药业有限公司 3 CYHS2601573 司美格鲁肽注射液 浙江三生蔓迪药业有限公司 3 CYHS2601572 司美格鲁肽注射液 浙江三生蔓迪药业有限公司 3 CYHS2601571 盐酸纳美芬注射液 远大医药(中国)有限公司 3 CYHS2601540 盐酸多巴胺注射液 江苏福邦药业有限公司 3 CYHS2601545 盐酸多巴胺注射液 江苏福邦药业有限公司 3 CYHS2601544 盐酸多巴胺注射液 江苏福邦药业有限公司 3 CYHS2601543 酮咯酸氨丁三醇片 重庆圣华曦药业股份有限公司 3 CYHS2601541 盐酸异丙肾上腺素注射液 四川美大康佳乐药业有限公司 3 CYHS2601553 帕拉米韦注射液 辰欣药业股份有限公司 3 CYHS2601554 盐酸异丙肾上腺素注射液 四川美大康佳乐药业有限公司 3 CYHS2601552 比拉斯汀口服溶液 珠海北杉生物科技有限公司 3 CYHS2601558 注射用盐酸兰地洛尔 康普药业股份有限公司 3 CYHS2601557 注射用盐酸兰地洛尔 福安药业集团湖北人民制药有限公司 3 CYHS2601533 依普利酮片 成都倍特药业股份有限公司 3 CYHS2601535 依普利酮片 成都倍特药业股份有限公司 3 CYHS2601534 注射用甲磺酸萘莫司他 成都青山利康药业股份有限公司 3 CYHS2601519 注射用甲磺酸萘莫司他 成都青山利康药业股份有限公司 3 CYHS2601518 醋酸钙片 黑龙江龙德药业有限公司 3 CYHS2601522 吡拉西坦注射液 成都华宇制药有限公司 3 CYHS2601521 乙酰半胱氨酸片 华益药业科技(安徽)有限公司 3 CYHS2601524 米诺地尔搽剂 安徽得宏生制药有限公司 3 CYHS2601529 盐酸丁卡因凝胶 湖南九典制药股份有限公司 3 CYHS2601527 盐酸丁卡因凝胶 湖南九典制药股份有限公司 3 CYHS2601526 瑞加诺生注射液 康普药业股份有限公司 3 CYHS2601525 氢溴酸吡西替尼片 南京海纳制药有限公司 4 CYHS2601577 依达拉奉右莰醇注射用浓溶液 四川健林药业有限责任公司 4 CYHS2601575 注射用阿莫西林钠克拉维酸钾 广州艾奇西新药研究有限公司 4 CYHS2601582 盐酸氨溴索口服溶液 江苏晨牌邦德药业有限公司 4 CYHS2601587 硫酸氨基葡萄糖胶囊 海南万玮制药有限公司 4 CYHS2601586 10%脂肪乳(OO)/5.5%氨基酸(15)/葡萄糖(20%)注射液 扬子江药业集团有限公司 4 CYHS2601585 阿达帕林过氧苯甲酰凝胶 广东江正药业有限公司 4 CYHS2601562 依折麦布阿托伐他汀钙片(Ⅰ)、(Ⅱ) 浙江普利药业有限公司 4 CYHS2601566 二十碳五烯酸乙酯软胶囊 浙江浙北药业有限公司 4 CYHS2601563 多替诺雷片 齐鲁制药有限公司 4 CYHS2601567 硫酸氨基葡萄糖胶囊 浙江前进药业有限公司 4 CYHS2601569 多替诺雷片 齐鲁制药有限公司 4 CYHS2601568 依折麦布阿托伐他汀钙片(Ⅰ)、(Ⅱ) 浙江普利药业有限公司 4 CYHS2601565 二十碳五烯酸乙酯软胶囊(II) 哈尔滨誉衡制药有限公司 4 CYHS2601539 乳果糖口服溶液 浙江美迪深生物医药有限公司 4 CYHS2601547 乳果糖口服溶液 浙江美迪深生物医药有限公司 4 CYHS2601546 盐酸氨溴索口服溶液 江苏欧歌制药有限公司 4 CYHS2601542 盐酸胺碘酮片 上海理想制药有限公司 4 CYHS2601549 盐酸胺碘酮片 上海理想制药有限公司 4 CYHS2601548 瑞维那新吸入溶液 扬子江药业集团有限公司 4 CYHS2601556 依达拉奉右莰醇注射用浓溶液 四川益生智同医药生物科技发展有限公司 4 CYHS2601555 四烯甲萘醌软胶囊 华夏国药(菏泽)制药有限公司 4 CYHS2601551 艾瑞昔布片 浙江华海制药科技有限公司 4 CYHS2601538 阿达帕林过氧苯甲酰凝胶 遂成药业股份有限公司 4 CYHS2601561 阿达帕林过氧苯甲酰凝胶 遂成药业股份有限公司 4 CYHS2601560 阿达帕林过氧苯甲酰凝胶 遂成药业股份有限公司 4 CYHS2601559 蛋白琥珀酸铁口服溶液 浙江普洛康裕制药有限公司 4 CYHS2601537 达罗他胺片 齐鲁制药(海南)有限公司 4 CYHS2601536 艾托格列净片 江苏德源药业股份有限公司 4 CYHS2601520 脂肪乳氨基酸(17)葡萄糖(19%)注射液 江苏明德制药有限公司 4 CYHS2601523 依巴斯汀片 江苏万高药业股份有限公司 4 CYHS2601530 莱博雷生片 江苏宣泰药业有限公司 4 CYHS2601528 氟哌噻吨美利曲辛片 远大医药(西安)有限公司 4 CYHS2601532 注射用阿奇霉素 武汉市小铂生物科技有限公司 4 CYHS2601531 环索奈德吸入气雾剂 上海上药信谊药厂有限公司 4 CYHL2600077 环索奈德吸入气雾剂 上海上药信谊药厂有限公司 4 CYHL2600076 进口申请 药品名称 企业 注册分类 受理号 氢溴酸尼罗司他片 MERCK SERONO LIMITED 5.1 JXHS2600074 氢溴酸尼罗司他片 MERCK SERONO LIMITED 5.1 JXHS2600073 帕博利珠单抗注射液 MSD International Business GmbH 2.2 JXSS2600056 AZD6234注射液 AstraZeneca AB 1 JXHL2600244 AZD6234注射液 AstraZeneca AB 1 JXHL2600243 AZD6234注射液 AstraZeneca AB 1 JXHL2600242 AZD6234注射液 AstraZeneca AB 1 JXHL2600241 AZD6234注射液 AstraZeneca AB 1 JXHL2600252 AZD6234注射液 AstraZeneca AB 1 JXHL2600250 AZD6234注射液 AstraZeneca AB 1 JXHL2600248 AZD6234注射液 AstraZeneca AB 1 JXHL2600247 AZD6234注射液 AstraZeneca AB 1 JXHL2600246 AZD6234注射液 AstraZeneca AB 1 JXHL2600245 AZD6234注射液 AstraZeneca AB 1 JXHL2600251 AZD6234注射液 AstraZeneca AB 1 JXHL2600249 AZD5305 AstraZeneca AB 1 JXHL2600257 PF-08653944注射液 Pfizer Inc. 1 JXHL2600256 PF-08653944注射液 Pfizer Inc. 1 JXHL2600255 PF-08653944注射液 Pfizer Inc. 1 JXHL2600254 PF-08653944注射液 Pfizer Inc. 1 JXHL2600253 Rinzimetostat (ORIC-944) ORIC Pharmaceuticals, Inc. 1 JXHL2600240 Golcadomide胶囊 Celgene Corporation 1 JXHL2600237 Golcadomide胶囊 Celgene Corporation 1 JXHL2600236 Golcadomide胶囊 Celgene Corporation 1 JXHL2600235 Golcadomide胶囊 Celgene Corporation 1 JXHL2600234 BMS-986458片 Bristol-Myers Squibb Company 1 JXHL2600233 BMS-986458片 Bristol-Myers Squibb Company 1 JXHL2600232 那米司特片 Boehringer lngelheim International GmbH 2.4 JXHL2600239 那米司特片 Boehringer lngelheim International GmbH 2.4 JXHL2600238 Rilzabrutinib片 Sanofi-Aventis Recherche & Developpement 2.4 JXHL2600231 Revumenib片 Syndax Pharmaceuticals, Inc. 2.4 JXHL2600230 Revumenib片 Syndax Pharmaceuticals, Inc. 2.4 JXHL2600229 Revumenib片 Syndax Pharmaceuticals, Inc. 2.4 JXHL2600228 DS-6000a Daiichi Sankyo, Inc. 1 JXSL2600151 中药相关申请 药品名称 企业 注册分类 受理号 柴芍肠宁颗粒 玉森(佛山)新药研发有限公司 1.1 CXZL2600058 骨龙胶囊 东阿阿胶股份有限公司 2.3 CXZL2600057 桃红四物汤颗粒 株洲千金药业股份有限公司 3.1 CXZS2600035 注：绿色字体部分为潜在首仿品种； 咸达数据2026年5月每月药讯已出！ 关注“咸达数据”，微信关键词回复 ” 年+月，如202605” 获得最新药迅！ 不包含原料药、医用氧、注射用水、氯化钠或葡萄糖注射液等申请，不包含再注册、一次性进口、技术转移、复审申请。

AstraZeneca and Daiichi Sankyo’sDatroway (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the 1st-line treatment of adult patients with unresectable or metastatic triple-negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the TROPION-Breast02 Phase III trial, which were presented at the 2025 European Society for Medical Oncology Congress and published in Annals of Oncology. Susan Galbraith, Executive Vice President, Oncology Haematology R&D, AstraZeneca, said: “As one of the hardest cancers to treat, today only 15% of patients with metastatic triple-negative breast cancer survive beyond five years. This positive opinion from the CHMP marks an important step forward in bringing the potential of Datroway to transform outcomes for patients with this type of cancer in the EU.” John Tsai, MD, Global Head, R&D, Daiichi Sankyo, said: “Triple-negative breast cancer remains one of the most aggressive types of breast cancer, with limited treatment options for patients with metastatic disease who are not candidates for immunotherapy and are currently treated with traditional chemotherapy. This positive recommendation by the CHMP underscores the potential for Datroway to replace traditional chemotherapy in this setting and we look forward to working closely with the EMA to bring this new indication to patients in the EU.” In the trial, Datroway demonstrated a statistically significant and clinically meaningful 5.0-month improvement in median overall survival (OS) (hazard ratio [HR] 0.79; 95% confidence interval [CI] 0.64-0.98; p=0.0291) compared to chemotherapy as 1st-line treatment in this patient population. Median OS was 23.7 months for patients treated with Datroway versus 18.7 months for those treated with chemotherapy. Datroway reduced the risk of disease progression or death by 43% compared to chemotherapy (HR 0.57; 95% CI 0.47-0.69; p<0.0001) as assessed by blinded independent central review (BICR). Datroway was also associated with more robust treatment responses, including an objective response rate (ORR) of 62.5% compared to an ORR of 29.3% with chemotherapy.1 The safety profile of Datroway in TROPION-Breast02 was consistent with previous clinical trials of Datroway in breast cancer. Datroway was approved in the US in May 2026 for the treatment of adult patients with unresectable or metastatic TNBC who are not candidates for PD-1/PD-L1 inhibitor therapy. Additional reviews are underway in China and Japan, as well as Australia, Canada, Singapore and Switzerland as part of Project Orbis. Datroway is a specifically engineered TROP2-directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo and being jointly developed and commercialised by AstraZeneca and Daiichi Sankyo. Notes Triple-negative breast cancer TNBC accounts for approximately 15% of all breast cancer cases, with an estimated 345,000 diagnoses globally each year.2,3 In Europe, there are an estimated 83,000 diagnoses of TNBC each year.2,4 TNBC is diagnosed more frequently in younger and premenopausal women, and is more prevalent in Black and Hispanic women.5-7 Metastatic TNBC is the most aggressive type of breast cancer and has one of the worst prognoses, with median OS of just 12 to 18 months and only about 15% of patients living five years following diagnosis.5,8,9 While some breast cancers may test positive for oestrogen receptors, progesterone receptors or overexpression of HER2, TNBC tests negative for all three.5 Due to its aggressive nature and absence of common breast cancer receptors, TNBC is characteristically difficult to treat.5 For patients with metastatic disease with PD-L1 expressing tumours, the addition of immunotherapy to chemotherapy has improved outcomes in the 1st-line setting.10,11However, for approximately 70% of patients with metastatic TNBC who are not candidates for immunotherapy, prior to the approval of Datroway, chemotherapy was the standard 1st-line treatment.12 TROP2 is a protein broadly expressed in several solid tumours, including TNBC.13 TROP2 is associated with increased tumour progression and poor survival in patients with breast cancer.14,15 TROPION-Breast02 TROPION-Breast02 is a global, multicentre, randomised, open-label Phase III trial evaluating the efficacy and safety of Datroway versus investigator’s choice of chemotherapy (paclitaxel, nab-paclitaxel, capecitabine, carboplatin or eribulin) in patients with previously untreated locally recurrent inoperable or metastatic TNBC for whom immunotherapy was not an option. This included patients whose tumours did not express PD-L1 as well as patients with PD-L1 expressing tumours who could not receive immunotherapy due to prior exposure in early-stage disease, comorbidities or immunotherapy not being accessible in their geography. Enrolment included patients with de novo or recurrent disease, regardless of disease-free interval, and those with poor prognostic factors such as stable brain metastases. The dual primary endpoints of TROPION-Breast02 are OS and progression-free survival (PFS) as assessed by blinded independent central review. Secondary endpoints include PFS as assessed by investigator, ORR, duration of response, disease control rate, pharmacokinetics and safety. TROPION-Breast02 enrolled 644 patients at sites in Africa, Asia, Europe, North America and South America. For more information, visit ClinicalTrials.gov. Datroway Datroway (datopotamab deruxtecan; datopotamab deruxtecan-dlnk in the US only) is a TROP2-directed ADC. Designed using Daiichi Sankyo’s proprietary DXd ADC Technology, Datroway is one of seven DXd ADCs in the oncology pipeline of Daiichi Sankyo, and one of the most advanced programmes in AstraZeneca’s ADC scientific platform. Datroway is comprised of a humanised anti-TROP2 IgG1 monoclonal antibody, developed in collaboration with Sapporo Medical University, attached to a number of topoisomerase I inhibitor payloads (an exatecan derivative, DXd) via tetrapeptide-based cleavable linkers. Datroway is also approved in more than 40 countries/regions worldwide for the treatment of adult patients with unresectable or metastatic HR-positive, HER2-negative (IHC 0, IHC 1+ or IHC 2+/ISH-) breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease based on results from the TROPION-Breast01 trial. Datroway is approved in the US for the treatment of adult patients with unresectable or metastatic TNBC who are not candidates for PD-1/PD-L1 inhibitor therapy based on the results from the TROPION-Breast02 trial. Datroway is available in the US under accelerated approval for the treatment of adult patients with locally advanced or metastatic EGFR-mutated non-small cell lung cancer (NSCLC) who have received prior EGFR-directed therapy and platinum-based chemotherapy based on results from the TROPION-Lung05 and TROPION-Lung01 trials. Continued approval for this indication in the US may be contingent upon verification and description of clinical benefit in a confirmatory trial. Datroway clinical development programme A comprehensive global clinical development programme is underway with more than 20 trials evaluating the efficacy and safety of Datroway across multiple cancers, including NSCLC, TNBC and urothelial cancer. The programme includes eight Phase III trials in lung cancer, five Phase III trials in breast cancer, and one Phase II/III trial in urothelial cancer evaluating Datroway as a monotherapy and in combination with other cancer treatments in various settings. Daiichi Sankyo collaboration AstraZeneca and Daiichi Sankyo entered into a global collaboration to jointly develop and commercialise Enhertu (trastuzumab deruxtecan) in March 2019 and Datroway in July 2020, except in Japan where Daiichi Sankyo maintains exclusive rights for each ADC. Daiichi Sankyo is responsible for the manufacturing and supply of Enhertu and Datroway. AstraZeneca in breast cancer Driven by a growing understanding of breast cancer biology, AstraZeneca is challenging, and redefining, the current clinical paradigm for how breast cancer is classified and treated to deliver even more effective treatments to patients in need – with the bold ambition to one day eliminate breast cancer as a cause of death. AstraZeneca has a comprehensive portfolio of approved and promising compounds in development that leverage different mechanisms of action to address the biologically diverse breast cancer tumour environment. With Enhertu, AstraZeneca and Daiichi Sankyo are aiming to improve outcomes in previously treated HER2-positive, HER2-low and HER2-ultralow metastatic breast cancer, and expanding its potential in earlier lines of treatment and in new breast cancer settings. In HR-positive breast cancer, AstraZeneca continues to improve outcomes with foundational medicines Faslodex (fulvestrant) and Zoladex (goserelin) and aims to reshape the HR-positive space with first-in-class AKT inhibitor, Truqap (capivasertib), the TROP2-directed ADC, Datroway, and next-generation oral SERD, Etcamah. PARP inhibitor Lynparza (olaparib) is a targeted treatment option that has been studied in early and metastatic breast cancer patients with an inherited BRCA mutation. AstraZeneca with MSD (Merck & Co., Inc. in the US and Canada) continue to research Lynparza in these settings. AstraZeneca is also exploring the potential of saruparib, a potent and selective inhibitor of PARP1, in combination with camizestrant in BRCA-mutated, HR-positive, HER2-negative advanced breast cancer. To bring much-needed treatment options to patients with triple-negative breast cancer, an aggressive form of breast cancer, AstraZeneca is collaborating with Daiichi Sankyo to evaluate the potential of Datroway alone and in combination with immunotherapy Imfinzi (durvalumab).  AstraZeneca in oncology AstraZeneca is leading a revolution in oncology with the ambition to provide cures for cancer in every form, following the science to understand cancer and all its complexities to discover, develop and deliver life-changing medicines to patients. The Company’s focus is on some of the most challenging cancers. It is through persistent innovation that AstraZeneca has built one of the most diverse portfolios and pipelines in the industry, with the potential to catalyse changes in the practice of medicine and transform the patient experience. AstraZeneca has the vision to redefine cancer care and, one day, eliminate cancer as a cause of death. AstraZeneca AstraZeneca (LSE/STO/NYSE: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialisation of prescription medicines in Oncology, Rare Disease, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca’s innovative medicines are sold in more than 125 countries and used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on Social Media @AstraZeneca. Contacts For details on how to contact the Investor Relations Team, please click here. For Media contacts, click here. References Matthew Bowden Company Secretary AstraZeneca PLC Oncology Corporate and financial